1
Eric First, M.D.
Eric R First: Application of botulinum toxin to the management of neurogenic inflammatory disorders. Thomas J Nutter McClennen & Fish Engellenner, May 16, 2000: US06063768 (160 worldwide citation)

The present invention provides a method for the use of at least one serotype or a combination of serotypes of Botulinum neurotoxin either alone or in combination with other peptides or fusion proteins, that when administered in a safe and effective amount, antagonize and therefore decrease or block ...


2
Thomas R Tice, Richard M Gilley, John H Eldridge, Jay K Staas, Melinda G Hollingshead, William M Shannon: Method of potentiating an immune response. Southern Research Institute, UAB Research Foundation, Needle & Rosenberg, December 24, 1991: US05075109 (232 worldwide citation)

A method of delivering a bioactive agent to an animal entailing the steps of encapsulating effective amounts of the agent in a biocompatible excipient to form microcapsules having a size ranging from between approximately one micrometer to approximately ten micrometers and admnistering effective amo ...


3
Robert M Platz, Mark A Winters, Colin G Pitt: Pulmonary administration of granulocyte colony stimulating factor. Amgen, Richard J Mazza, February 8, 1994: US05284656 (188 worldwide citation)

Granulocyte-colony stimulating factor (G-CSF) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration in a ...


4
David B Weiner, William V Williams, Bin Wang: Genetic immunization. The Wistar Institute, The Trustees of the University of Pennsylvania, Woodcock Washburn Kurtz Mackiewicz & Norris, January 14, 1997: US05593972 (157 worldwide citation)

Methods of prophylactic and therapeutic immunization of an individual against pathogen infection, diseases associated with hyperproliferative cells and autoimmune diseases are disclosed. The methods comprise the steps of administering to cells of an individual, a nucleic acid molecule that comprises ...


5
David B Weiner, William V Williams, Bin Wang: Genetic immunization. The Trustees of the University of Pennsylvania, The Wistar Institute, Woodcock Washburn Kurtz Mackiewicz & Norris, October 6, 1998: US05817637 (90 worldwide citation)

Methods of prophylactic and therapeutic immunization of an individual against pathogen infection, diseases associated with hyperproliferative cells and autoimmune diseases are disclosed. The methods comprise the steps of administering to cells of an individual, a nucleic acid molecule that comprises ...


6
Stephen D Gillies: Recombinant antibody cytokine fusion proteins. Testa Hurwitz & Thibeault, July 22, 1997: US05650150 (90 worldwide citation)

Immunoconjugates for the selective delivery of a cytokine to a target cell are disclosed. The fusion proteins are comprised of an immunoglobulin heavy chain having a specificity for the target cell, such as a cancer or virus-infected cell, and a cytokine, such as lymphotoxin, tumor necrosis factor a ...


7
Danute E Nitecki, Nandini Katre, Robert J Goodson, Lois Aldwin: Preparation of a polymer/interleukin-2 conjugate. Cetus Corporation, Philip L McGarrigle, February 18, 1992: US05089261 (89 worldwide citation)

The present invention is a process for preparing a pharmaceutical composition comprising a biologically active conjugated protein. It comprises a polyethylene glycol or a polyoxyethylated polyol conjugated to IL-2. This protein is conjugated to reduce its immunogenicity, and increase its solubility, ...


8
David F Ranney: Endothelial envelopment drug carriers. Arnold White & Durkee, May 15, 1990: US04925678 (86 worldwide citation)

This application describes the preparation and in vivo testing of surface coatings and matrix materials, which when applied to or caused to comprise the carriers for drugs and diagnostic agents, and administered in a fashion that allows efficient vascular access, causes the carriers to recognize det ...


9
John Hakimi, Patricia Kilian, Perry Rosen: Polyethylene-protein conjugates. Hoffmann La Roche, George W Johnston, William H Epstein, Catherine R Smith, September 24, 1996: US05559213 (84 worldwide citation)

The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein whic ...


10
David M Neville Jr, Richard J Youle: Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant. John S Roberts Jr, November 16, 1982: US04359457 (84 worldwide citation)

A tumor suppressive composition active against lymphoma consisting of an injection of hybrid protein anti Thy 1.2 monoclonal antibody-ricin and hyperosmotic lactose. The inoculation i.v. of murine tissues in vivo by lymphoma is made at -20 to -25 days and the tumor suppressant composition is used i. ...